2006
MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases
Mason GF, Krystal JH. MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases. NMR In Biomedicine 2006, 19: 690-701. PMID: 16986118, DOI: 10.1002/nbm.1080.Peer-Reviewed Original ResearchConceptsPsychiatric diseasesMagnetic resonance spectroscopyGlial abnormalitiesPsychiatric disordersBiochemical markersNon-invasive techniqueNeuropsychiatric disordersPotential roleDrug developmentDrug discoveryMRS techniquesDiseaseDisordersStudy of mechanismsTreatmentLines of investigationAbnormalitiesNeurochemistryDrug delivery
1999
Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion
Bunney W, Azarnoff D, Brown B, Cancro R, Gibbons R, Gillin J, Hullett S, Killam K, Kupfer D, Krystal J, Stolley P, French G, Pope A. Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion. JAMA Psychiatry 1999, 56: 349-352. PMID: 10197830, DOI: 10.1001/archpsyc.56.4.349.Peer-Reviewed Original ResearchAdverse Drug Reaction Reporting SystemsChronic DiseaseDrug ApprovalDrug EvaluationEvaluation Studies as TopicHumansHypnotics and SedativesNational Academies of Science, Engineering, and Medicine, U.S., Health and Medicine DivisionPrevalenceProduct Surveillance, PostmarketingProfessional Staff CommitteesRandomized Controlled Trials as TopicResearch DesignSleep Initiation and Maintenance DisordersTriazolamUnited StatesUnited States Food and Drug Administration